Related Experiment Video
Updated: May 28, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Update upon efficacy and safety of TNF-α inhibitors
Abstract:
The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Therapeutic Drug Monitoring: Affecting Factors
Drug Products: Biologics, Biosimilars and Interchangeables
Myocarditis IV: Nursing Management
Clinical Trials: Overview
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
